Product Information
ZTLIDO 1.8% TOPICAL SYSTEM is a brand product labeled by Scilex Pharmaceuticals Inc., priced at $12.3060 per EA under NDC 69557011130. Its NADAC has been published 398 times since Feb 20, 2019.
FDA first approved this application on Feb 28, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Lidocaine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
36 mg/1
Manufacturer
Scilex Pharmaceuticals Inc.NDC
69557011130
Classification
Brand
Dosage Form
PATCH
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
LIDOCAINEApproval Type
New Drug (NDA)
FDA Application
NDA207962FDA Approved
2/28/2018
TE Code
AB
On Market Since
4/26/2018
Pharmacological Classes
Price Statistics
The NADAC for ZTLIDO 1.8% TOPICAL SYSTEM has been published 398 times since Feb 20, 2019, and over the history we have for it it has risen 43.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3060 per EA |
|---|---|
| All-time high | $12.3221 (May 13, 2026) |
| All-time low | $8.6028 (Feb 20, 2019) |
| 52-week high | $12.3221 |
| 52-week low | $12.0027 |
| Median price | $9.7974 |
| Average price | $10.4055 |
| Largest weekly change | +9.8% (Feb 8, 2023) |
| Weeks tracked | 398 |
| Tracking since | Feb 20, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Lidocaine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Scilex Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lidocaine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Amide Local Anesthetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZTLIDO 1.8% TOPICAL SYSTEM?
The current National Average Drug Acquisition Cost (NADAC) for ZTLIDO 1.8% TOPICAL SYSTEM, manufactured by Scilex Pharmaceuticals Inc., is $12.3060 per EA (NDC 69557011130), effective Sep 30, 2026.
How has the price of ZTLIDO 1.8% TOPICAL SYSTEM changed over time?
Over the history we have for it, the NADAC for ZTLIDO 1.8% TOPICAL SYSTEM has risen 43.0%. It has been tracked across 398 weekly CMS publications since Feb 20, 2019.
What are the highest and lowest recorded NADAC prices for ZTLIDO 1.8% TOPICAL SYSTEM?
Since Feb 20, 2019, the NADAC for ZTLIDO 1.8% TOPICAL SYSTEM has ranged from a low of $8.6028 (Feb 20, 2019) to a high of $12.3221 (May 13, 2026), with a median of $9.7974 per EA.
Are there cheaper alternatives to ZTLIDO 1.8% TOPICAL SYSTEM?
No other NADAC-published product currently shares the active ingredient and strength of ZTLIDO 1.8% TOPICAL SYSTEM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZTLIDO 1.8% TOPICAL SYSTEM?
ZTLIDO 1.8% TOPICAL SYSTEM (NDC 69557011130) is labeled by Scilex Pharmaceuticals Inc., and CMS classifies it as a brand product.